Metformin

Generic Name: Metformin

Brand Names: Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo

Drug Type: Small Molecule

Chemical Formula: C_₄H_₁₁N_₅

CAS Number: 657-24-9

Unique Ingredient Identifier: 9100L32L2N

Background: Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
...

Indication: Metformin immediate-release formulations

Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.

Metformin extended-release tablet (XR)
...

Associated Conditions: Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate

Associated Therapies: -

Clinical Trials

Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: vildagliptin
Drug: glimepiride
Drug: Metformin
Drug: Vildagliptin matching placebo
Drug: Glimepiride matching placebo

First Posted Date: 2005-03-23

Last Posted Date: 2020-12-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 3118

Registration Number: NCT00106340

Locations: 🇩🇪
Investigative Centers, Nurnberg, Germany
🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States

The Effects of Metformin on Blood Vessel Structure and Function

Phase 2

Completed

Conditions: Hypertension
Hypercholesterolemia
Hyperglycemia
Obesity

Interventions: Drug: Placebo
Drug: Metformin

First Posted Date: 2005-03-04

Last Posted Date: 2017-01-18

Lead Sponsor: National Institute on Aging (NIA)

Target Recruit Count: 77

Registration Number: NCT00105066

Locations: 🇺🇸
National Institute on Aging (NIA), Harbor Hospital, Baltimore, Maryland, United States

Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Gliclazide
Drug: vildagliptin
Drug: Metformin

First Posted Date: 2005-01-31

Last Posted Date: 2020-12-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1007

Registration Number: NCT00102466

Locations: 🇩🇪
Investigative Centers, Nurnberg, Germany
🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland

Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Insulin glargine
Drug: exenatide
Drug: Metformin

First Posted Date: 2004-11-25

Last Posted Date: 2015-04-07

Lead Sponsor: AstraZeneca

Target Recruit Count: 69

Registration Number: NCT00097500

Locations: 🇸🇪
Research Site, Goteborg, Sweden

Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

First Posted Date: 2004-11-22

Last Posted Date: 2017-01-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 230

Registration Number: NCT00097279

Locations: 🇺🇸
Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States

Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Metformin

First Posted Date: 2004-07-05

Last Posted Date: 2016-02-05

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 353

Registration Number: NCT00086502

Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)

Phase 3

Completed

Conditions: Diabetes Mellitus, Type II

Interventions: Drug: Sitagliptin (MK0431)
Drug: Placebo/Glipizide 5 mg
Drug: Metformin
Drug: Pioglitazone

First Posted Date: 2004-07-05

Last Posted Date: 2017-05-05

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 701

Registration Number: NCT00086515

Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY)

Phase 3

Completed

Conditions: Diabetes Mellitus, Type II

Interventions: Drug: Metformin
Behavioral: Lifestyle Program
Drug: Rosiglitazone

First Posted Date: 2004-04-12

Last Posted Date: 2021-07-30

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 699

Registration Number: NCT00081328

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
George Washington University Biostatistics Center, Rockville, Maryland, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States

and more 13 locations

Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)

Phase 3

Completed

Conditions: Fatty Liver

Interventions: Drug: Matching placebo
Dietary Supplement: Vitamin E
Drug: Metformin

First Posted Date: 2003-07-03

Last Posted Date: 2012-09-27

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 173

Registration Number: NCT00063635

Locations: 🇺🇸
University of California, San Diego, San Diego, California, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States

and more 7 locations

Treating Nonalcoholic Steatohepatitis (NASH) With Metformin

Phase 2

Completed

Conditions: Hepatitis

First Posted Date: 2003-06-24

Last Posted Date: 2011-07-20

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 28

Registration Number: NCT00063232

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy